1. Home
  2. Medical Research
  3. Palo Alto, CA
  4. Arc Research Institute

Arc Research Institute

Arc Research Institute has an America's Best Score of 56 out of 100, based on its 2024 Form 990, below the 60-point bar to be ranked.

  • Palo Alto, CA
  • Tax-exempt since 2022
  • EIN: 87-1920284
arcinstitute.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
56OF 100 Not ranked Below the 60-point bar How this score is calculated

Organization summary

Arc Research Institute is a 501(c)(3) organization, classified under Medical Research (NTEE H99). Contributions are tax-deductible.

3181 Porter Dr, Palo Alto, CA 94304-1213

Among the 5 scored medical research organizations in Palo Alto, Arc Research Institute holds 14.6 months of operating reserves (peer median 14.6 months), runs a typical yearly surplus of 47.7% (peers: surplus of 29.0%), and has grown spending 58.9% a year (peers: grown spending 3.5% a year).

In fiscal year 2024 it reported $122,280,682 in revenue and $82,781,856 in expenses, with contributions making up 98.5% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2024 Form 990

Our mission is to accelerate scientific progress, understand the root causes of disease, and narrow the gap between discoveries and impact on patients.

Main program · fiscal year 2024

  • - Core Investigators (which include the following labs) are provided with no-strings-attached, multi-year funding as well as cutting-edge scientific and infrastructure support to enable high-risk, high-reward science. They are innovative pioneers enabled to pursue their very best ideas. The Gilbert lab has an expertise in synthetic biology, functional genomics and cancer biology. We build CRISPR e… Read more

    - Core Investigators (which include the following labs) are provided with no-strings-attached, multi-year funding as well as cutting-edge scientific and infrastructure support to enable high-risk, high-reward science. They are innovative pioneers enabled to pursue their very best ideas. The Gilbert lab has an expertise in synthetic biology, functional genomics and cancer biology. We build CRISPR epigenetic editing tools to turn genes on and off and to perturb gene regulatory elements. We are developing CRISPR functional genomics approaches to map individual genes or sets of genes that regulate phenotypes of interest in vitro and in vivo. We are focused on utilizing our expertise to tackle big problems in deadly human cancers such as metastasis and drug resistance. The Hsu Lab works at the intersection of synthetic biology and genomics to invent new biotechnologies for improving human health. The Konermann lab develops and applies next-generation functional genomics to understand the cellular and molecular pathways underlying the neuronal system and neurodegenerative disease, with the long-term goal of developing rationally targeted therapeutics for neurodegenerative disorders. The Li Lab combines chemistry, biochemistry, immunology, and physiology to uncover basic mechanisms in innate immunity and, in parallel, develop therapeutic hypotheses and lead molecules. Innate immune pathways as the first line of defense against pathogens present many exciting opportunities for scientists from many disciplines. These pathways are a rich source of novel chemistry: they involve diverse molecular patterns in pathogens, little-explored second messengers, and drugs with poorly understood mechanism. Activation of innate immunity is a proven therapeutic strategy for vaccination, viral infection, and cancer, while inhibition is a strategy for treating autoimmune diseases and neurodegeneration. To date, however, most modulators of innate immunity are broad, non-specific, and poorly characterized, such as killed bacteria, alum crystals, and steroids. The Li lab seeks to improve understanding of these pathways and facilitate the development of more precise drugs for preventing or treating specific diseases. The Horns Lab creates and uses new technologies to understand and manipulate cells. We aim to discover the fundamental principles governing how cells and tissues operate, and to harness these insights to improve human health. Our work unites molecular engineering, synthetic biology, and genomics to answer questions and solve problems in immunology, neuroscience, cancer, and aging. The Goodarzi Lab combines modern experimental and computational technologies to understand complex human diseases at a molecular level. We are predominantly focused on metastatic progression in multiple cancers and neurodegenerative diseases as the biggest challenges to human health in the 21st century. - Technology Development Centers As biomedical research has become more advanced, it has become more dependent on complicated tooling that is difficult or impossible for any single lab to pursue today. Arc Technology Centers are focused on advancing and distributing key biomedical technologies within the institute that require high capital scale, targeted expertise, and systematic innovation. Our Technology Centers provide long-term career options for Arc scientists beyond their training period. By enabling competitive compensation relative to the biotech and tech industries (such as for research scientists and computer programmers), our goal is to expand the ecosystem of available career paths in research and maintain continuity in critical technical know-how. We have 5 staffed Technology Centers focused on 1. Cellular Models 2. Genome Engineering 3. Mammalian Models 4. Multi-omics 5. Computational biology - Translational Programs Making an impact on complex diseases requires new fundamental biological insights into disease mechanisms and new technologies that can target rational therapeutic pathways at the right place and time in the body. In addition to curiosity-driven knowledge building, producing medically useful discoveries is a core mission of Arc. Arc will build translational infrastructure to support the distribution of new biological insights and biotechnologies into the clinical environment. This branch of the institute will be dedicated to reducing the friction of transferring academic research into for-profit spin-outs. This includes a streamlined IP licensing process, funding support, and an advisory network of drug development and domain experts. We will also create focused, entrepreneurial teams dedicated to testing specific ideas, such as a new gene target or effector molecule, within the institute. Our goal is to empower Arc scientists, engineers, and inventors to accelerate their work into impact on patients.

    $64,083,480 spent

Where each dollar went · fiscal year 2024

Of every dollar it spent, 77¢ went to programs, 23¢ to management and 0¢ to fundraising.

  • Programs $64,083,480
  • Management $18,698,376
  • Fundraising $0

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score56 / 100
DesignationNot ranked

Score breakdown

MeasureThis organizationPoints
Operating reserves14.6 mo; 6.3 mo in cash10.1 / 25
Financial balance (median margin)+47.7%6.7 / 20
Transparency3 full 990s, latest TY202420 / 20
Program growth+58.9% / yr15 / 15
Track record4 years1.6 / 10
Debt load45.4% of assets2.9 / 10
Total56.3 → 56
Spending on programs
Not scored; America's Best needs 65%+
77%Meets

Compared with Palo Alto peers

MeasureThis organizationPeer median
Operating reserves14.6 mo14.6 mo
Typical margin+47.7%+29.0%
Spending growth+58.9% / yr+3.5% / yr
Debt load45.4%45.4%

Peers: the 5 Palo Alto medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$122,280,682Fiscal year 20242022: $96,576,02820222023: $53,611,44420232024: $122,280,6822024
Expenses$82,781,856Fiscal year 20242022: $32,795,12220222023: $64,203,69820232024: $82,781,8562024
Total assets$184,388,461Fiscal year 20242022: $150,115,61920222023: $155,698,19620232024: $184,388,4612024
Total liabilities$83,668,141Fiscal year 20242022: $77,639,34920222023: $93,814,18020232024: $83,668,1412024
Fiscal year ending December 2024
Revenue$122,280,682
Expenses$82,781,856
Net income$39,498,826
Net assets$100,720,320

Notable sources of revenue

Percent of total revenue
Contributions$120,446,690
Program services$166,647
Investment income$1,667,345
Other (net)$0

Assets / debt

Total assets$184,388,461
Total liabilities$83,668,141
Net assets$100,720,320

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$53,611,444
Expenses$64,203,698
Net income−$10,592,254
Net assets$61,884,016

Notable sources of revenue

Percent of total revenue
Contributions$52,978,731
Program services$0
Investment income$632,713
Other (net)$0

Assets / debt

Total assets$155,698,196
Total liabilities$93,814,180
Net assets$61,884,016

Compensation

Officers and key employees$3,193,251
Share of expenses5.0%
Fiscal year ending December 2022
Revenue$96,576,028
Expenses$32,795,122
Net income$63,780,906
Net assets$72,476,270

Notable sources of revenue

Percent of total revenue
Contributions$97,360,040
Program services$0
Investment income$300,142
Other (net)−$1,084,154

Assets / debt

Total assets$150,115,619
Total liabilities$77,639,349
Net assets$72,476,270

Compensation

Officers and key employees$1,405,920
Share of expenses4.3%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?